1. Home
  2. OCX vs IGC Comparison

OCX vs IGC Comparison

Compare OCX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCX
  • IGC
  • Stock Information
  • Founded
  • OCX 2009
  • IGC 2005
  • Country
  • OCX United States
  • IGC United States
  • Employees
  • OCX N/A
  • IGC N/A
  • Industry
  • OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • OCX Health Care
  • IGC Health Care
  • Exchange
  • OCX Nasdaq
  • IGC Nasdaq
  • Market Cap
  • OCX 35.1M
  • IGC 29.4M
  • IPO Year
  • OCX N/A
  • IGC N/A
  • Fundamental
  • Price
  • OCX $2.01
  • IGC $0.31
  • Analyst Decision
  • OCX Buy
  • IGC Strong Buy
  • Analyst Count
  • OCX 3
  • IGC 2
  • Target Price
  • OCX $4.42
  • IGC $3.75
  • AVG Volume (30 Days)
  • OCX 53.0K
  • IGC 367.3K
  • Earning Date
  • OCX 11-12-2024
  • IGC 02-18-2025
  • Dividend Yield
  • OCX N/A
  • IGC N/A
  • EPS Growth
  • OCX N/A
  • IGC N/A
  • EPS
  • OCX N/A
  • IGC N/A
  • Revenue
  • OCX $709,000.00
  • IGC $1,183,000.00
  • Revenue This Year
  • OCX N/A
  • IGC N/A
  • Revenue Next Year
  • OCX $106.34
  • IGC $13.38
  • P/E Ratio
  • OCX N/A
  • IGC N/A
  • Revenue Growth
  • OCX N/A
  • IGC N/A
  • 52 Week Low
  • OCX $1.92
  • IGC $0.27
  • 52 Week High
  • OCX $3.48
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • OCX 42.58
  • IGC 35.18
  • Support Level
  • OCX $1.99
  • IGC $0.31
  • Resistance Level
  • OCX $2.30
  • IGC $0.33
  • Average True Range (ATR)
  • OCX 0.12
  • IGC 0.02
  • MACD
  • OCX 0.02
  • IGC -0.00
  • Stochastic Oscillator
  • OCX 25.70
  • IGC 3.89

About OCX Oncocyte Corporation

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: